JP2021533766A5 - - Google Patents

Info

Publication number
JP2021533766A5
JP2021533766A5 JP2021507552A JP2021507552A JP2021533766A5 JP 2021533766 A5 JP2021533766 A5 JP 2021533766A5 JP 2021507552 A JP2021507552 A JP 2021507552A JP 2021507552 A JP2021507552 A JP 2021507552A JP 2021533766 A5 JP2021533766 A5 JP 2021533766A5
Authority
JP
Japan
Prior art keywords
seq
cdr1
cdr2
cdr3
dab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021507552A
Other languages
English (en)
Japanese (ja)
Other versions
JP7416762B2 (ja
JP2021533766A (ja
Filing date
Publication date
Priority claimed from GBGB1813178.9A external-priority patent/GB201813178D0/en
Application filed filed Critical
Publication of JP2021533766A publication Critical patent/JP2021533766A/ja
Publication of JP2021533766A5 publication Critical patent/JP2021533766A5/ja
Priority to JP2023182454A priority Critical patent/JP2023178408A/ja
Application granted granted Critical
Publication of JP7416762B2 publication Critical patent/JP7416762B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021507552A 2018-08-13 2019-08-13 抗ｃｄ３３、抗ｃｌｌ１、ならびに少なくとも１つのさらなるｃａｒ抗ｃｄ１２３および／または抗ｆｔｌ３を含むｃａｒ ｔ細胞 Active JP7416762B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023182454A JP2023178408A (ja) 2018-08-13 2023-10-24 抗ｃｄ３３、抗ｃｌｌ１、ならびに少なくとも１つのさらなるｃａｒ抗ｃｄ１２３および／または抗ｆｔｌ３を含むｃａｒ ｔ細胞

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1813178.9A GB201813178D0 (en) 2018-08-13 2018-08-13 Cell
GB1813178.9 2018-08-13
PCT/GB2019/052275 WO2020035676A1 (en) 2018-08-13 2019-08-13 Car t-cells comprising an anti cd33, an anti cll1 and at least one further car anti cd123 and/or ftl3

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023182454A Division JP2023178408A (ja) 2018-08-13 2023-10-24 抗ｃｄ３３、抗ｃｌｌ１、ならびに少なくとも１つのさらなるｃａｒ抗ｃｄ１２３および／または抗ｆｔｌ３を含むｃａｒ ｔ細胞

Publications (3)

Publication Number Publication Date
JP2021533766A JP2021533766A (ja) 2021-12-09
JP2021533766A5 true JP2021533766A5 (https=) 2022-06-02
JP7416762B2 JP7416762B2 (ja) 2024-01-17

Family

ID=63667077

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021507552A Active JP7416762B2 (ja) 2018-08-13 2019-08-13 抗ｃｄ３３、抗ｃｌｌ１、ならびに少なくとも１つのさらなるｃａｒ抗ｃｄ１２３および／または抗ｆｔｌ３を含むｃａｒ ｔ細胞
JP2023182454A Pending JP2023178408A (ja) 2018-08-13 2023-10-24 抗ｃｄ３３、抗ｃｌｌ１、ならびに少なくとも１つのさらなるｃａｒ抗ｃｄ１２３および／または抗ｆｔｌ３を含むｃａｒ ｔ細胞

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023182454A Pending JP2023178408A (ja) 2018-08-13 2023-10-24 抗ｃｄ３３、抗ｃｌｌ１、ならびに少なくとも１つのさらなるｃａｒ抗ｃｄ１２３および／または抗ｆｔｌ３を含むｃａｒ ｔ細胞

Country Status (8)

Country Link
US (2) US20230330139A1 (https=)
EP (1) EP3837284A1 (https=)
JP (2) JP7416762B2 (https=)
CN (4) CN118878688A (https=)
AU (1) AU2019321066A1 (https=)
CA (1) CA3109752A1 (https=)
GB (1) GB201813178D0 (https=)
WO (1) WO2020035676A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202110873A (zh) * 2019-04-30 2021-03-16 美商聖堤生物科技股份有限公司 嵌合受體及其使用方法
CN115768463A (zh) * 2020-02-21 2023-03-07 哈普恩治疗公司 Flt3结合蛋白及使用方法
WO2022099175A1 (en) * 2020-11-09 2022-05-12 2Seventy Bio, Inc. Cd33 targeted immunotherapies
CN113045658B (zh) 2020-12-11 2021-12-24 广州百暨基因科技有限公司 抗cll1抗体及其应用
CN113234169B (zh) * 2020-12-11 2022-11-01 广州百暨基因科技有限公司 靶向cll1嵌合抗原受体及其应用
CN113248621B (zh) * 2020-12-11 2022-11-04 广州百暨基因科技有限公司 Cll1和cd33双靶点嵌合抗原受体及其应用
CN115197330B (zh) * 2021-04-14 2023-04-28 广州百暨基因科技有限公司 同时靶向cll1和cd33的嵌合抗原受体及其应用
US20250082681A1 (en) * 2021-07-30 2025-03-13 Nanjing Legend Biotech Co., Ltd. Antibodies against cll1 and constructs thereof
US20250082754A1 (en) * 2021-07-30 2025-03-13 Nanjing Legend Biotech Co., Ltd. Anti-cd33 antibodies and uses thereof
CN116018351A (zh) * 2021-08-16 2023-04-25 上海优替济生生物医药有限公司 靶向cd123的抗体、嵌合抗原受体及其用途
CN116063490A (zh) * 2021-09-07 2023-05-05 苏州晟济药业有限公司 一种vhh抗体或其抗原片段的突变体及其用途
WO2023205876A1 (en) * 2022-04-29 2023-11-02 Novobind Livestock Therapeutics Inc. Antibodies against disease causing agents of plants and uses thereof
GB202209920D0 (en) 2022-07-06 2022-08-17 Autolus Ltd Cell
CN116239690B (zh) * 2022-12-27 2024-01-30 四川大学 一种抗cd123的纳米抗体及其制备方法和应用
CN117482246B (zh) * 2022-12-30 2024-10-15 英百瑞(杭州)生物医药有限公司 抗cd33/cll1双特异性抗体-自然杀伤细胞偶联物及其用途
CN117964760B (zh) * 2023-12-21 2024-09-03 四川大学华西医院 抗人cll1/cd3的双特异性抗体及其应用
WO2026015644A1 (en) * 2024-07-10 2026-01-15 The Trustees Of The University Of Pennsylvania Cadherin-17 targeting antigen biding polypeptides, chimeric antigen receptors, car-t cells and methods of treating cadherin-17 positive cancers
GB202414617D0 (en) 2024-10-04 2024-11-20 Chancellor Masters And Scholars Of The Univ Of Oxford Immunotherapy

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8536310B2 (en) 2007-10-17 2013-09-17 Arca Biopharma, Inc. Antibodies to CLL-1
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
US9163090B2 (en) 2012-05-07 2015-10-20 Cellerant Therapeutics, Inc. Antibodies specific for CLL-1
MX373687B (es) 2013-11-21 2020-07-07 Ucl Business Ltd Célula natural (nk)
GB201405845D0 (en) 2014-04-01 2014-05-14 Ucl Business Plc Signalling system
SG10201913782UA (en) * 2014-07-21 2020-03-30 Novartis Ag Treatment of cancer using a cll-1 chimeric antigen receptor
GB201415347D0 (en) 2014-08-29 2014-10-15 Ucl Business Plc Signalling system
MA40579A (fr) 2014-09-12 2016-03-17 Genentech Inc Anticorps anti-cll-1 et immunoconjugués
BR112017013981A2 (pt) * 2015-01-26 2018-01-02 Cellectis receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer
GB201501936D0 (en) 2015-02-05 2015-03-25 Ucl Business Plc Signalling system
GB201503133D0 (en) 2015-02-24 2015-04-08 Ucl Business Plc And Syncona Partners Llp Chimeric protein
JP2018509148A (ja) * 2015-03-11 2018-04-05 セレクティスＣｅｌｌｅｃｔｉｓ 患者における持続性および／または生着を増加させるために同種ｔ細胞を改変する方法
GB201507115D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
US10501545B2 (en) 2015-06-16 2019-12-10 Genentech, Inc. Anti-CLL-1 antibodies and methods of use
US11655452B2 (en) * 2015-06-25 2023-05-23 Icell Gene Therapeutics Inc. Chimeric antigen receptors (CARs), compositions and methods of use thereof
WO2018028647A1 (en) * 2016-08-10 2018-02-15 Legend Biotech Usa Inc. Chimeric antigen receptors targeting bcma and methods of use thereof
CN105384825B (zh) * 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
EP3341410B1 (en) * 2015-08-24 2021-06-02 Cellectis Chimeric antigen receptors with integrated controllable functions
GB201518817D0 (en) * 2015-10-23 2015-12-09 Autolus Ltd Cell
CN109715808A (zh) * 2016-04-15 2019-05-03 诺华股份有限公司 用于选择性蛋白质表达的组合物和方法
GB201607968D0 (en) * 2016-05-06 2016-06-22 Crescendo Biolog Ltd Chimeric antigen receptor

Similar Documents

Publication Publication Date Title
JP2021533766A5 (https=)
CN106604932B (zh) 人白细胞介素-2的免疫刺激单克隆抗体
JP2021522844A5 (https=)
JP2020525032A5 (https=)
CN114502591B (zh) 靶向bcma的抗体、双特异性抗体及其用途
JP2021514664A5 (https=)
JP2021534762A5 (https=)
JP2021511811A5 (https=)
JP2020511152A5 (https=)
JP2019536430A5 (https=)
WO2016176322A1 (en) Methods of sequencing, determining, pairing, and validating therapeutic agents and disease specific antigens
JP2020503870A5 (https=)
JP2016196468A5 (https=)
JP2023526774A5 (https=)
JP2021528047A5 (https=)
JP2010511388A5 (https=)
JP2024531409A5 (https=)
JP2023508740A5 (https=)
JP2014088414A5 (https=)
JP2008543339A5 (https=)
JP2021524275A5 (https=)
JP2022511735A5 (https=)
JP2010509931A5 (https=)
JP2010504743A5 (https=)
JP2021517459A5 (https=)